PMID- 30616303
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 2005-6648 (Electronic)
IS  - 1226-3303 (Print)
IS  - 1226-3303 (Linking)
VI  - 35
IP  - 2
DP  - 2020 Mar
TI  - Clinical impact of anti-thymocyte globulin on survival and graft-versus-host 
      disease in patients undergoing human leukocyte antigen mismatched allogeneic stem 
      cell transplantation.
PG  - 429-437
LID - 10.3904/kjim.2018.317 [doi]
AB  - BACKGROUND/AIMS: Rabbit anti-thymocyte globulin (ATG) is usually incorporated in 
      hematopoietic stem cell transplantation (HSCT) to reduce the incidence of 
      graft-versus-host disease (GVHD). This study aimed to find optimal ATG doses in 
      patients undergoing human leukocyte antigen (HLA)-mismatched allogeneic HSCT. 
      METHODS: We retrospectively collected medical records from 352 consecutive 
      patients with acute myeloid leukemia (n = 214), acute lymphoblastic leukemia (n = 
      62), or myelodysplastic syndrome (n = 76) in eight centers of Korea between 2005 
      and 2015. All patients received busulfan-based conditioning without total body 
      irradiation (TBI) and received stem cells from HLA-mismatched donors. RESULTS: In 
      the current study, 5-year overall survival rates of patients receiving low to 
      medium doses of ATG (2.5 to 7.5 mg/kg) were higher than those receiving other 
      doses of ATG (hazard ratio [HR], 0.528; 95% confidence interval [CI], 0.311 to 
      0.897; p = 0.018). The incidence rates of extensive chronic GVHD (ecGVHD) after 
      administration of low to medium doses of ATG were lower than those after other 
      doses of ATG (HR, 0.447; 95% CI, 0.224 ton 0.889; p = 0.022). CONCLUSION: The low 
      to medium doses of ATG may be associated with improving survival outcomes and 
      reducing incidence of ecGVHD without enhancing the chances of relapse in patients 
      with acute leukemia or myelodysplastic syndrome undergoing non-TBI-based 
      HLA-mismatched allogeneic HSCT.
FAU - Kim, Taeyun
AU  - Kim T
AD  - Department of Internal Medicine, Kosin University Gospel Hospital, Busan, Korea.
FAU - Choi, Yunsuk
AU  - Choi Y
AD  - Department of Hematology and Oncology, Ulsan University Hospital, University of 
      Ulsan College of Medicine, Ulsan, Korea.
FAU - Lee, Je-Hwan
AU  - Lee JH
AD  - Department of Hematology, Asan Medical Center, University of Ulsan College of 
      Medicine, Seoul, Korea.
FAU - Park, Silvia
AU  - Park S
AD  - Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University 
      School of Medicine, Seoul, Korea.
FAU - Ahn, Jae-Sook
AU  - Ahn JS
AD  - Department of Internal Medicine, Chonnam National University Hwasun Hospital, 
      Hwasun, Korea.
FAU - Moon, Joon-Ho
AU  - Moon JH
AD  - Department of Hematology, Kyungpook National University Hospital, Daegu, Korea.
FAU - Shin, Ho-Jin
AU  - Shin HJ
AD  - Department of Internal Medicine, Pusan National University Hospital, Busan, 
      Korea.
FAU - Lee, Won Sik
AU  - Lee WS
AD  - Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, 
      Korea.
FAU - Kim, Dajung
AU  - Kim D
AD  - Department of Internal Medicine, Kosin University Gospel Hospital, Busan, Korea.
FAU - Lee, Ho Sup
AU  - Lee HS
AD  - Department of Internal Medicine, Kosin University Gospel Hospital, Busan, Korea.
LA  - eng
PT  - Journal Article
DEP - 20190110
PL  - Korea (South)
TA  - Korean J Intern Med
JT  - The Korean journal of internal medicine
JID - 8712418
RN  - 0 (Antilymphocyte Serum)
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Antilymphocyte Serum/adverse effects
MH  - *Graft vs Host Disease/etiology/prevention & control
MH  - HLA Antigens
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Humans
MH  - Republic of Korea
MH  - Retrospective Studies
MH  - Transplantation Conditioning/adverse effects
PMC - PMC7061010
OTO - NOTNLM
OT  - Allogeneic hematopoietic stem cell transplantation
OT  - Antithymocyte globulin
OT  - Graft vs host disease
OT  - Human leukocyte antigen mismatch
OT  - Survival
COIS- No potential conflict of interest relevant to this article was reported.
EDAT- 2019/01/09 06:00
MHDA- 2021/06/25 06:00
PMCR- 2020/03/01
CRDT- 2019/01/09 06:00
PHST- 2017/12/27 00:00 [received]
PHST- 2018/05/04 00:00 [accepted]
PHST- 2019/01/09 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PHST- 2019/01/09 06:00 [entrez]
PHST- 2020/03/01 00:00 [pmc-release]
AID - kjim.2018.317 [pii]
AID - kjim-2018-317 [pii]
AID - 10.3904/kjim.2018.317 [doi]
PST - ppublish
SO  - Korean J Intern Med. 2020 Mar;35(2):429-437. doi: 10.3904/kjim.2018.317. Epub 
      2019 Jan 10.